An expedited code stroke protocol is feasible and safe

被引:39
作者
Sattin, Justin A.
Olson, Scott E.
Liu, Lin
Raman, Rema
Lyden, Patrick D.
机构
[1] Univ Calif San Diego, Sch Med, Dept Neurosci, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA
[3] Vet Adm Med Ctr, Neurol Serv, San Diego, CA USA
关键词
acute care; health resources/utilization; stroke management; thrombolysis;
D O I
10.1161/01.STR.0000249057.44420.4b
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose - Stroke recovery critically depends on timely reperfusion. In July 2003, we set a benchmark onset-to-treatment time of <= 2 hours and instituted an expedited code stroke protocol to accomplish this. We aim to show that the protocol is feasible and safe. Methods - The expedited protocol includes: Benchmark onset-to-treatment within 2 hours; in-person triage of all code stroke patients; unmixed tissue plasminogen activator at the bedside during evaluation; no delays pending coagulation tests, chest x-ray, or stool guiac unless specifically indicated; and no delays pending formal CT interpretation or written consent. Results - Between July 2003 and June 2005, we evaluated 781 patients and treated 103 of 781 (13.2%) with intravenous recombinant tissue plasminogen activator within 3 hours. Of these, we treated 49 of 103 (47.6%) within 2 hours of symptom onset, and 54 of 103 (52.4%) between 2 and 3 hours. The overall risk of symptomatic intracerebral hemorrhage was 4 of 103 (3.9%; 95% CI, 1.1%, 9.6%), and not significantly different from 6.4% (P = 0.42). The hemorrhage risks in those treated within 2 hours of symptom onset and those treated between 2 and 3 hours were not significantly different from each other or from 6.4%. Conclusions - The expedited code stroke protocol is feasible and appears safe. Further study is warranted to confirm its safety and determine whether it results in better clinical outcomes.
引用
收藏
页码:2935 / 2939
页数:5
相关论文
共 17 条
  • [1] Guidelines for the early management of patients with ischemic stroke - A scientific statement from the Stroke Council of the American Stroke Association
    Adams, HP
    Adams, RJ
    Brott, T
    del Zoppo, GJ
    Furlan, A
    Goldstein, LB
    Grubb, RL
    Higashida, R
    Kidwell, C
    Kwiatkowski, TG
    Marler, JR
    Hademenos, GJ
    [J]. STROKE, 2003, 34 (04) : 1056 - 1083
  • [2] Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility
    Barber, PA
    Zhang, J
    Demchuk, AM
    Hill, MD
    Buchan, AM
    [J]. NEUROLOGY, 2001, 56 (08) : 1015 - 1020
  • [3] Thrombolysis for acute stroke in routine clinical practice
    Bravata, DM
    Kim, N
    Concato, J
    Krumholz, HM
    Brass, LM
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (17) : 1994 - 2001
  • [4] URGENT THERAPY FOR STROKE .1. PILOT-STUDY OF TISSUE PLASMINOGEN-ACTIVATOR ADMINISTERED WITHIN 90 MINUTES
    BROTT, TG
    HALEY, EC
    LEVY, DE
    BARSAN, W
    BRODERICK, J
    SHEPPARD, GL
    SPILKER, J
    KONGABLE, GL
    MASSEY, S
    REED, R
    MARLER, JR
    [J]. STROKE, 1992, 23 (05) : 632 - 640
  • [5] Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial
    Clark, WM
    Wissman, S
    Albers, GW
    Jhamandas, JH
    Madden, KP
    Hamilton, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2019 - 2026
  • [6] The rtPA (Alteplase) 0-to 6-hour acute stroke trial, part A (A0276g) - Results of a double-blind, placebo-controlled, multicenter study
    Clark, WM
    Albers, GW
    Madden, KP
    Hamilton, S
    [J]. STROKE, 2000, 31 (04) : 811 - 816
  • [7] Intravenous tissue-type plasminogen activator therapy for ischemic stroke - Houston experience 1996 to 2000
    Grotta, JC
    Burgin, WS
    El-Mitwalli, A
    Long, M
    Campbell, M
    Morgenstern, LB
    Malkoff, M
    Alexandrov, AV
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (12) : 2009 - 2013
  • [8] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
    Hacke, W
    Kaste, M
    Fieschi, C
    von Kummer, R
    Davalos, A
    Meier, D
    Larrue, V
    Bluhmki, E
    Davis, S
    Donnan, G
    Schneider, D
    Diez-Tejedor, E
    Trouillas, P
    [J]. LANCET, 1998, 352 (9136) : 1245 - 1251
  • [9] HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
  • [10] Hacke W, 2004, LANCET, V363, P768